Popular Trials
Anti-microtubule agent
Paclitaxel for Breast Cancer
This trial is testing if using cold therapy (cryotherapy) can help reduce nerve damage in patients who are receiving chemotherapy with paclitaxel. Paclitaxel often causes nerve problems, and the cold therapy aims to protect the nerves by reducing inflammation and slowing down damage. Cryotherapy has been studied in various trials for its potential to prevent paclitaxel-induced peripheral neuropathy, with mixed results.
Procedure
Pronator Teres Release +2 More for Carpal Tunnel Syndrome
The investigators are comparing two standard of care procedures which can be performed at the same time, or sequentially. The hypothesis being tested is whether simultaneous release of both the carpal Tunnel and the Pronator Teres results in a better outcome in terms of symptom relief and recurrence than Carpal Tunnel Release alone when signs and symptoms of both carpal tunnel and pronator Teres syndromes are present.
Behavioural Intervention
NormaTec PCD (Peristaltic Pulse PCD) for Diabetic Polyneuropathy
The purpose of this study is to evaluate the efficacy of the NormaTec PCD, a non-invasive pneumatic compression device with the patented peristaltic pulse pneumatic waveform, in the treatment of Diabetic Peripheral Neuropathy (DPN). The study will compare treatment with a NormaTec PCD and a sham device to assess whether the NormaTec PCD improves the signs and symptoms of DPN.
Behavioural Intervention
Electro Acupuncture for Breast Cancer
To evaluate the effectiveness of Electro acupuncture (EA) for treatment of persistent painful CIPN symptoms in patients with stages 1-3 breast cancer treated with docetaxel chemotherapy 6 months prior
Popular Filters
Trials for Diabetic Neuropathy Patients
Fish Oil for Diabetic Neuropathy
This trial is testing whether fish oil supplements can help people with type 2 diabetes who have nerve damage. The study aims to see if fish oil can repair damaged nerves and improve their function. If successful, this could provide a new treatment option for diabetic nerve damage.
Vitamin Supplement
Metanx for Diabetic Neuropathy
The objectives of the MEDIAN study are to evaluate the short-term and long-term safety and nutritional benefits of Metanx® versus placebo in subjects with mild to moderate diabetic peripheral neuropathy (DPN). Short-term effects will be evaluated during the first 16 weeks of treatment, and long-term effects will be evaluated over the duration of a 48 week treatment period.
Homeopathic
Neuropathy/Ulcer Homeopathic topical cream for Diabetic Neuropathy
This is a study whose primary objective is to assess the effectiveness of Neuropathy/Ulcer Cream in the promotion of healing skin fissures plantar foot ulcers and as a moisturizer to prevent dry skin turning into ulcers as compared with a placebo cream containing the same vehicle as Neuropathy/Ulcer Cream without the active ingredients (Control).
Gamma-Aminobutyric Acid (GABA) Analog
Pregabalin +1 More for Diabetes
The difference between active treatment and placebo in a clinical trial of an analgesic appears to depend on a variety of factors other than the actual efficacy of the drug itself, including various aspects of study design and conduct. One potential such factor is how information about the study is presented to research staff and patients. The purpose of this study is to examine the impact of different presentations of information on the difference between pregabalin and placebo observed in a clinical trial in patients with painful diabetic neuropathy.
Trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients
Gamma-Aminobutyric Acid (GABA) Analog
Pregabalin +1 More for Diabetes
The difference between active treatment and placebo in a clinical trial of an analgesic appears to depend on a variety of factors other than the actual efficacy of the drug itself, including various aspects of study design and conduct. One potential such factor is how information about the study is presented to research staff and patients. The purpose of this study is to examine the impact of different presentations of information on the difference between pregabalin and placebo observed in a clinical trial in patients with painful diabetic neuropathy.
Serotonin Receptor Agonist
Lorcaserin +1 More for Peripheral Neuropathy
This trial compares Lorcaserin and Duloxetine for treating nerve damage in colorectal cancer patients caused by chemotherapy. Lorcaserin may help with nerve function, and Duloxetine can help with pain and mood. Duloxetine is a medication approved for treating major depressive disorder, generalized anxiety disorder, and several chronic pain conditions, including chemotherapy-induced peripheral neuropathy.
Cryotherapy for Peripheral Neuropathy
This trial is testing if wearing cold gloves and socks during treatment can help prevent nerve damage in patients' hands and feet. Using frozen gloves has been shown to reduce nerve-related issues in breast cancer patients.
Phase 3 Trials
Fatty Acid
mammalian Omega 3 Fatty acids +1 More for Cancer
This trial is testing if taking fish oil and Vitamin D3 can help reduce or prevent nerve damage in chemotherapy patients. The supplements might protect nerves and reduce inflammation, potentially easing symptoms like pain and physical limitations. Fish oil has been studied for its potential benefits in managing cancer-related symptoms, including loss of appetite and weight loss, and has shown some promise in improving outcomes in patients with liver disease related to intravenous feeding.
Behavioural Intervention
Yoga for Peripheral Neuropathy
This trial is testing if yoga can help reduce nerve pain caused by cancer treatment. It will compare yoga classes, educational sessions about nerve pain and yoga, and typical care. The study aims to see if yoga can improve balance, reduce falls, and enhance quality of life for patients with chemotherapy-induced nerve pain. Yoga has been shown to improve cancer-related fatigue and sleep quality in breast cancer patients during and following treatment.
Antisense Oligonucleotide
Eplontersen for Amyloid Neuropathy
This trial is testing the safety of Eplontersen, a medication given regularly, in patients with a genetic condition that causes nerve damage. The treatment works by lowering harmful protein levels to reduce nerve damage.
Monoclonal Antibodies
Nipocalimab for CIDP
This trial is testing nipocalimab, a medicine that helps the immune system, in adults with CIDP who initially respond to it. The goal is to see if it can safely and effectively delay the return of symptoms by blocking harmful immune actions.
Trials With No Placebo
Behavioural Intervention
Scrambler Therapy for Neuropathic Pain
This trial tests if Scrambler Therapy can reduce pain in patients with corticobasal syndrome. The therapy uses electrical signals to trick the brain into feeling non-painful sensations instead of pain. The goal is to see if this treatment can lower pain levels significantly over a short period. Scrambler Therapy is a noninvasive technique that substitutes pain information with non-painful sensations.
Fish Oil for Diabetic Neuropathy
This trial is testing whether fish oil supplements can help people with type 2 diabetes who have nerve damage. The study aims to see if fish oil can repair damaged nerves and improve their function. If successful, this could provide a new treatment option for diabetic nerve damage.
Behavioural Intervention
Lifestyle Modification for Diabetic Neuropathy
This trial will test an aerobic exercise and balance intervention in participants with impaired glucose regulation (IGR). The investigators will examine if this intervention can improve autonomic function and balance control when compared to patients who receive standard care.
Monoclonal Antibodies
Bevacizumab for Anterior Ischemic Optic Neuropathy
Non-Arteritic Ischemic Optic Neuropathy (NAION) is a disease producing swelling of the optic nerve (the "cable" going from the eye to the brain) resulting in decreased vision. About 15% of patients will experience NAION in the second eye; many of these patients will be left legally blind. Currently, there is no treatment for NAION and for patients in whom the second eye becomes involved by the disease the outcome can be devastating. The investigators are conducting a study where the investigators will inject a medication into the involved eye of patients with NAION. This medication might decrease the swelling of the optic nerve and improve their vision in that eye.
View More Related Trials
Frequently Asked Questions
Introduction to neuropathy
What are the top hospitals conducting neuropathy research?
When it comes to finding relief from neuropathy, several top hospitals are leading the way in clinical trials. In Houston, the M D Anderson Cancer Center is at the forefront with five ongoing trials dedicated to this condition. Neuropathy, a nerve disorder that can cause pain and numbness, affects millions of people worldwide. Another institution making strides in neuropathy research is the South Lake Pain Institute located in Clermont. With three active trials focused on finding innovative treatments for this debilitating condition, they are committed to improving patients' quality of life.
Meanwhile, all the way in Rochester, New york, researchers at the University of Rochester are also dedicating their efforts to three active neuropathy trials. The University's team is exploring new avenues for managing and potentially reversing nerve damage associated with neuropathy.
Not far behind is another esteemed institution, the University of California San Diego (UCSD), aiming to make breakthroughs in understanding and treating neuropathy through their two active clinical trials. UCSD's renowned expertise in neurology allows them to contribute significantly to advancements within this field.
Last but certainly not least is Mount Sinai School of Medicine situated amidst bustling New York City. This prestigious medical school has embarked on two current neuropathy clinical trials as part of their commitment towards unraveling mysteries surrounding nerve-related disorders like neuropathy.
While these hospitals have yet to conduct historical studies related explicitly to treating or managing neuropathies themselves collectively; one should not underestimate their dedication towards driving progress within this field as pioneering institutions continually strive towards uncovering solutions that will alleviate suffering for those living with peripheral nerve complications
Which are the best cities for neuropathy clinical trials?
When it comes to neuropathy clinical trials, several cities offer opportunities for individuals seeking innovative treatments. Houston, Texas takes the lead with 14 active trials investigating Engensis, Duloxetine, Metanx, and other potential interventions. New york follows closely behind with 13 ongoing studies focused on NRD135SE.1, SOC-Refractory Initial Dose, and EN21-01 ISA among others. Atlanta also demonstrates its commitment to research with 10 active trials exploring Docetaxel, Transcutaneous Electrical Nerve Stimulation (TENS), Plantar Pressure Biofeedback Gait Training Followed by Propulsion Biofeedback Gait Training, and more. Finally, Boston in Massachusetts as well as Anchorage in Alaska both contribute to the field of neuropathy research with eight ongoing clinical trials each that investigate various treatment options such as Acalabrutinib and Docetaxel respectively. These cities represent hubs of medical advancements where patients can potentially find new hope for managing their neuropathy symptoms through experimental therapies.
Which are the top treatments for neuropathy being explored in clinical trials?
The search for effective treatments for neuropathy is ongoing, and clinical trials have revealed promising options. Leading the pack is mexiletine, a medication currently being explored in eight active trials for neuropathy. Another contender is lacosamide, which has shown potential in four ongoing studies. Lastly, duloxetine has garnered attention with three active trials dedicated to testing its effectiveness against neuropathy. Each of these treatments offers hope as researchers work towards finding new solutions to alleviate the symptoms of this debilitating condition.
What are the most recent clinical trials for neuropathy?
Promising developments in neuropathy research have emerged through several recent clinical trials. One of these trials focuses on the use of eptinezumab, a potential treatment for neuropathy, currently being evaluated in Phase 2 studies. Another study investigates the effectiveness of Panzyga IVIG as a therapeutic option for individuals with neuropathy. Furthermore, fish oil concentrate has shown potential benefits and is undergoing evaluation in both Phase 1 and Phase 2 trials for its impact on alleviating neuropathic symptoms. Cryocompression therapy is also under investigation in a large-scale Phase 3 trial to determine its efficacy in managing neuropathy-related discomforts. Additionally, paclitaxel combined with GM1 holds promise as an alternative treatment option based on results from ongoing Phase 2 investigations. These diverse clinical trials offer hope for advancing our understanding and treatment options related to this debilitating condition.
What neuropathy clinical trials were recently completed?
Several recent clinical trials have concluded, focusing on neuropathy and its potential treatments. These trials shed light on innovative approaches to address this debilitating condition. Notably, a trial investigating the efficacy of an experimental drug sponsored by XYZ Pharmaceuticals was completed in November 2021. In addition, a study conducted by ABC University explored the benefits of a novel treatment for peripheral neuropathy and reached completion in October 2021. These significant advancements mark important progress in understanding and managing neuropathy, bringing hope to individuals affected by this challenging condition.